GLP-1 medicines cause malnutrition in 22% of patients. Multivitamins are often inadequate. Patients need dietitian support ...

Telemedicine prescriptions of semaglutide and tirzepatide, combined with a virtual behavioral program, yielded weight loss ...

The WHO released new guidance on GLP-1 medications for adults with obesity, recommending their long-term, continuous use when ...

Semaglutide shows potential for weight loss in older adults without harming bone density, but longer studies are essential to ...

Semaglutide, the drug behind weight-loss jabs Ozempic and Wegovy, does not slow cognitive decline among people with ...

Two large-scale phase 3 trials found that semaglutide did not significantly slow cognitive decline in early-stage Alzheimer’s ...

The drug tested was Rybelsus, a pill approved only for type 2 diabetes. Like Novo's blockbusters Ozempic and Wegovy, it ...

A higher dose of semaglutide achieves a 19% loss in body weight and redefines the limits of obesity treatment.

GLP-1 agonist drugs essentially mimic the hormone’s action. Quite a few have been developed, including semaglutide, ...

FDA and WHO identified semaglutide suicidal thought reports, exceeding those of other diabetes medications in their adverse ...